Minerva Neurosciences (NERV) Q1 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on CNS diseases, with lead candidate roluperidone for schizophrenia and MIN-301 for Parkinson's disease; no commercialized products or product revenue to date.

• FDA issued a Complete Response Letter (CRL) for roluperidone in February 2024, requiring additional studies and data for approval; company continues to engage with FDA.

• Regained compliance with Nasdaq listing requirements in March 2025, ensuring continued trading and subject to a one-year monitoring period.

• Accumulated deficit reached $399.1 million as of March 31, 2025; net loss for Q1 2025 was $3.8 million, down from $8.6 million in Q1 2024.

• Cash, cash equivalents, and restricted cash totaled $17.4 million at quarter end, expected to fund operations for at least 12 months.

Financial highlights

• Research and development expenses decreased to $1.4 million in Q1 2025 from $4.2 million in Q1 2024, mainly due to lower NDA review and study costs.

• General and administrative expenses were stable at $2.5 million for both Q1 2025 and Q1 2024.

• Net loss per share improved to $(0.50) in Q1 2025 from $(1.13) in Q1 2024.

• No revenue generated from product sales or licenses; investment income was $158,000 in Q1 2025, down from $358,000 in Q1 2024.

• No non-cash interest expense for the sale of future royalties in Q1 2025, compared to $2.3 million in Q1 2024, due to revised royalty payment estimates.

Outlook and guidance

• Expects continued operating losses and negative cash flows as clinical and regulatory activities progress.

• Additional capital will be required to advance roluperidone and other candidates; may seek equity, debt, or strategic partnerships.

• Cash on hand projected to cover operating commitments for at least the next 12 months.

• Management continues to focus on resolving FDA concerns for roluperidone and maintaining Nasdaq compliance.

• Forward-looking statements highlight risks related to regulatory outcomes, capital needs, and general economic conditions.